Biomarkers of spinal cord injury and ensuing bladder dysfunction

Advanced Drug Delivery Reviews

Volumn 82, Issue , 2015, Pages 153-159

  Cruz, Célia Duarte ^a,b   Coelho, Ana ^a,b   Antunes Lopes, Tiago ^a,b,c   Cruz, Francisco ^a,b,c  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Inflammatory biomarkers; Neurogenic detrusor overactivity; Neuroimaging; Regeneration; Spinal cord injury; Structural biomarkers; Urinary bladder

Indexed keywords

NEUROIMAGING; NEUROLOGY; PATIENT REHABILITATION; PROTEINS;

DAMAGED CELLS; FUNCTIONAL CHANGES; NEUROGENIC DETRUSOR OVERACTIVITY; NEUROLOGICAL DEFICIT; NEUROLOGICAL RECOVERIES; REGENERATION; SPINAL CORD INJURIES (SCI); URINARY BLADDER;

BIOMARKERS;

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CHEMOKINE; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1BETA; MAJOR BASIC PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEURON SPECIFIC ENOLASE; PROTEIN S100B; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR; AUTACOID; NERVE PROTEIN;

BLADDER CONTRACTION; BLADDER DYSFUNCTION; BLADDER EMPTYING; BLADDER SPHINCTER; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; DETRUSOR DYSSYNERGIA; DIFFUSION TENSOR IMAGING; HUMAN; LOWER URINARY TRACT SYMPTOM; NEUROFILAMENT; NEUROGENIC BLADDER; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERACTIVE BLADDER; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY; SPINAL CORD TRANSSECTION; TRAUMATIC BRAIN INJURY; URINE INCONTINENCE; ANIMAL; COMPLICATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; URINARY BLADDER DISEASES;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION MEDIATORS; NERVE TISSUE PROTEINS; NEUROIMAGING; SPINAL CORD INJURIES; URINARY BLADDER DISEASES;

EID: 84927129630     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.11.007     Document Type: Review

References (105)

1. Silver J., Miller J.H. Regeneration beyond the glial scar. Nat. Rev. Neurosci. 2004 Feb, 5:146-156.
2. Ramer L.M., Ramer M.S., Steeves J.D. Setting the stage for functional repair of spinal cord injuries: a cast of thousands. Spinal Cord 2005 Mar, 43:134-161.
3. Bradbury E.J., Carter L.M. Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury. Brain Res. Bull. 2010 Jul, 8.
4. Bradbury E.J., McMahon S.B. Spinal cord repair strategies: why do they work?. Nat. Rev. Neurosci. 2006 Aug, 7:644-653.
5. Curt A., Van Hedel H.J., Klaus D., Dietz V. Recovery from a spinal cord injury: significance of compensation, neural plasticity, and repair. J. Neurotrauma 2008 Jun, 25:677-685.
6. Fawcett J.W., Curt A., Steeves J.D., et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007 Mar, 45:190-205.
7. Kwon B.K., Casha S., Hurlbert R.J., Yong V.W. Inflammatory and structural biomarkers in acute traumatic spinal cord injury. Clin. Chem. Lab. Med. CCLM FESCC 2011 Mar, 49:425-433.
8. Burns A.S., Lee B.S., Ditunno J.F., Tessler A. Patient selection for clinical trials: the reliability of the early spinal cord injury examination. J. Neurotrauma 2003 May, 20:477-482.
9. van den Berg M.E., Castellote J.M., Mahillo-Fernandez I., de Pedro-Cuesta J. Incidence of spinal cord injury worldwide: a systematic review. Neuroepidemiology 2010, 34:184-192. (discussion 92).
10. Ma V.Y., Chan L., Carruthers K.J. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch. Phys. Med. Rehabil. 2014 May, 95:986-995. (e1).
11. Wyndaele M., Wyndaele J.J. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey?. Spinal Cord 2006 Sep, 44:523-529.
12. French D.D., Campbell R.R., Sabharwal S., Nelson A.L., Palacios P.A., Gavin-Dreschnack D. Health care costs for patients with chronic spinal cord injury in the Veterans Health Administration. J. Spinal Cord Med. 2007, 30:477-481.
13. New P.W., Cripps R.A., Bonne Lee B. Global maps of non-traumatic spinal cord injury epidemiology: towards a living data repository. Spinal Cord 2013 Jan, 15.
14. New P.W., Jackson T. The costs and adverse events associated with hospitalization of patients with spinal cord injury in Victoria, Australia. Spine 2010 Apr 1, 35:796-802.
15. Frisbie J.H., Kache A. Increasing survival and changing causes of death in myelopathy patients. J. Am. Paraplegia Soc. 1983 Jul, 6:51-56.
16. French J.S., Anderson-Erisman K.D., Sutter M. What do spinal cord injury consumers want? A review of spinal cord injury consumer priorities and neuroprosthesis from the 2008 neural interfaces conference. Neuromodulation J. Int. Neuromodulation Soc. 2010 Jul, 13:229-231.
17. Krueger H., Noonan V.K., Trenaman L.M., Joshi P., Rivers C.S. The economic burden of traumatic spinal cord injury in Canada. Chron. Dis. Inj. Can. 2013 Jun, 33:113-122.
18. Selvarajah S., Hammond E.R., Haider A.H., et al. The burden of acute traumatic spinal cord injury among adults in the united states: an update. J. Neurotrauma 2014 Feb 1, 31:228-238.
19. Mahabaleshwarkar R., Khanna R. National hospitalization burden associated with spinal cord injuries in the United States. Spinal Cord 2014 Feb, 52:139-144.
20. Biomarkers, surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001 Mar, 69:89-95.
21. Pouw M.H., Hosman A.J., van Middendorp J.J., Verbeek M.M., Vos P.E., van de Meent H. Biomarkers in spinal cord injury. Spinal Cord 2009 Jul, 47:519-525.
22. Yokobori S., Hosein K., Burks S., Sharma I., Gajavelli S., Bullock R. Biomarkers for the clinical differential diagnosis in traumatic brain injury-a systematic review. CNS Neurosci. Ther. 2013 Aug, 19:556-565.
23. Kosik K.S., Caceres A. Tau protein and the establishment of an axonal morphology. J. Cell Sci. Suppl. 1991, 15:69-74.
24. Paglini G., Peris L., Mascotti F., Quiroga S., Caceres A. Tau protein function in axonal formation. Neurochem. Res. 2000 Jan, 25:37-42.
25. Shiiya N., Kunihara T., Miyatake T., Matsuzaki K., Yasuda K. Tau protein in the cerebrospinal fluid is a marker of brain injury after aortic surgery. Ann. Thorac. Surg. 2004 Jun, 77:2034-2038.
26. Kwon B.K., Stammers A.M., Belanger L.M., et al. Cerebrospinal fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J. Neurotrauma 2010 Apr, 27:669-682.
27. Roerig A., Carlson R., Tipold A., Stein V.M. Cerebrospinal fluid tau protein as a biomarker for severity of spinal cord injury in dogs with intervertebral disc herniation. Vet. J. 2013 Aug, 197:253-258.
28. Ost M., Nylen K., Csajbok L., et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 2006 Nov 14, 67:1600-1604.
29. Yokobori S., Zhang Z., Moghieb A., et al. Acute diagnostic biomarkers for spinal cord injury: review of the literature and preliminary research report. World Neurosurg. 2013 Mar, 19.
30. Lasek R.J., Phillips L., Katz M.J., Autilio-Gambetti L. Function and evolution of neurofilament proteins. Ann. N. Y. Acad. Sci. 1985, 455:462-478.
31. Perrot R., Berges R., Bocquet A., Eyer J. Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol. Neurobiol. 2008 Aug, 38:27-65.
32. Yuan A., Rao M.V., Veeranna, Nixon R.A. Neurofilaments at a glance. J. Cell Sci. 2012 Jul 15, 125:3257-3263.
33. Strong M.J., Strong W.L., Jaffe H., Traggert B., Sopper M.M., Pant H.C. Phosphorylation state of the native high-molecular-weight neurofilament subunit protein from cervical spinal cord in sporadic amyotrophic lateral sclerosis. J. Neurochem. 2001 Mar, 76:1315-1325.
34. Shaw G., Yang C., Ellis R., et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem. Biophys. Res. Commun. 2005 Nov 4, 336:1268-1277.
35. Anderson K.J., Scheff S.W., Miller K.M., et al. The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J. Neurotrauma 2008 Sep, 25:1079-1085.
36. Hayakawa K., Okazaki R., Ishii K., et al. Phosphorylated neurofilament subunit NF-H as a biomarker for evaluating the severity of spinal cord injury patients, a pilot study. Spinal Cord 2012 Jul, 50:493-496.
37. Nishida H., Nakayama M., Tanaka H., et al. Evaluation of serum phosphorylated neurofilament subunit NF-H as a prognostic biomarker in dogs with thoracolumbar intervertebral disc herniation. Vet. Surg. VS 2014 Jan, 27.
38. Winnerkvist A., Anderson R.E., Hansson L.O., et al. Multilevel somatosensory evoked potentials and cerebrospinal proteins: indicators of spinal cord injury in thoracoabdominal aortic aneurysm surgery. Eur. J. Cardiothorac. Surg. Off. J. Eur. Assoc. Cardiothorac. Surg. 2007 Apr, 31:637-642.
39. Guez M., Hildingsson C., Rosengren L., Karlsson K., Toolanen G. Nervous tissue damage markers in cerebrospinal fluid after cervical spine injuries and whiplash trauma. J. Neurotrauma 2003 Sep, 20:853-858.
40. Marangos P.J., Schmechel D.E. Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu. Rev. Neurosci. 1987, 10:269-295.
41. Cao F., Yang X.F., Liu W.G., et al. Elevation of neuron-specific enolase and S-100beta protein level in experimental acute spinal cord injury. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2008 May, 15:541-544.
42. Loy D.N., Sroufe A.E., Pelt J.L., et al. Serum biomarkers for experimental acute spinal cord injury: rapid elevation of neuron-specific enolase and S-100beta. Neurosurgery 2005 Feb, 56:391-397. (discussion-7).
43. Marquardt G., Setzer M., Theisen A., Tews D.S., Seifert V. Experimental subacute spinal cord compression: correlation of serial S100B and NSE serum measurements, histopathological changes, and outcome. Neurol. Res. 2011 May, 33:421-426.
44. Brisby H., Olmarker K., Rosengren L., Cederlund C.G., Rydevik B. Markers of nerve tissue injury in the cerebrospinal fluid in patients with lumbar disc herniation and sciatica. Spine 1999 Apr 15, 24:742-746.
45. Marquardt G., Setzer M., Szelenyi A., Seifert V., Gerlach R. Significance of serial S100b and NSE serum measurements in surgically treated patients with spondylotic cervical myelopathy. Acta Neurochir. 2009 Nov, 151:1439-1443.
46. Eng L.F., Vanderhaeghen J.J., Bignami A., Gerstl B. An acidic protein isolated from fibrous astrocytes. Brain Res. 1971 May 7, 28:351-354.
47. Zhang J., Zhang C.H., Lin X.L., Zhang Q., Wang J., Shi S.L. Serum glial fibrillary acidic protein as a biomarker for differentiating intracerebral hemorrhage and ischemic stroke in patients with symptoms of acute stroke: a systematic review and meta-analysis. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2013 Nov, 34:1887-1892.
48. Zhang Z., Mondello S., Kobeissy F., et al. Protein biomarkers for traumatic and ischemic brain injury: from bench to bedside. Transl. Stroke Res. 2011 Dec, 2:455-462.
49. Papa L., Lewis L.M., Falk J.L., et al. Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann. Emerg. Med. 2012 Jun, 59:471-483.
50. Lumpkins K.M., Bochicchio G.V., Keledjian K., Simard J.M., McCunn M., Scalea T. Glial fibrillary acidic protein is highly correlated with brain injury. J. Trauma 2008 Oct, 65:778-782. (discussion 82-4).
51. Harauz G., Ishiyama N., Hill C.M., Bates I.R., Libich D.S., Fares C. Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron 2004, 35:503-542.
52. Liu M.C., Akle V., Zheng W., et al. Extensive degradation of myelin basic protein isoforms by calpain following traumatic brain injury. J. Neurochem. 2006 Aug, 98:700-712.
53. Ottens A.K., Golden E.C., Bustamante L., Hayes R.L., Denslow N.D., Wang K.K. Proteolysis of multiple myelin basic protein isoforms after neurotrauma: characterization by mass spectrometry. J. Neurochem. 2008 Mar, 104:1404-1414.
54. Zhang B., Huang Y., Su Z., et al. Neurological, functional, and biomechanical characteristics after high-velocity behind armor blunt trauma of the spine. J. Trauma 2011 Dec, 71:1680-1688.
55. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int. J. Biochem. Cell Biol. 2001 Jul, 33:637-668.
56. Ma J., Novikov L.N., Karlsson K., Kellerth J.O., Wiberg M. Plexus avulsion and spinal cord injury increase the serum concentration of S-100 protein: an experimental study in rats. Scand. J. Plast. Reconstr. Surg. Hand Surg. 2001 Dec, 35:355-359. (Nordisk plastikkirurgisk forening [and] Nordisk klubb for handkirurgi).
57. van Dongen E.P., Ter Beek H.T., Boezeman E.H., Schepens M.A., Langemeijer H.J., Aarts L.P. Normal serum concentrations of S-100 protein and changes in cerebrospinal fluid concentrations of S-100 protein during and after thoracoabdominal aortic aneurysm surgery: is S-100 protein a biochemical marker of clinical value in detecting spinal cord ischemia?. J. Vasc. Surg. 1998 Feb, 27:344-346.
58. Chatfield D.A., Zemlan F.P., Day D.J., Menon D.K. Discordant temporal patterns of S100beta and cleaved tau protein elevation after head injury: a pilot study. Br. J. Neurosurg. 2002 Oct, 16:471-476.
59. Routsi C., Stamataki E., Nanas S., et al. Increased levels of serum S100B protein in critically ill patients without brain injury. Shock 2006 Jul, 26:20-24.
60. Jaerve A., Muller H.W. Chemokines in CNS injury and repair. Cell Tissue Res. 2012 Jul, 349:229-248.
61. Pineau I., Sun L., Bastien D., Lacroix S. Astrocytes initiate inflammation in the injured mouse spinal cord by promoting the entry of neutrophils and inflammatory monocytes in an IL-1 receptor/MyD88-dependent fashion. Brain Behav. Immun. 2010 May, 24:540-553.
62. Knerlich-Lukoschus F., Juraschek M., Blomer U., Lucius R., Mehdorn H.M., Held-Feindt J. Force-dependent development of neuropathic central pain and time-related CCL2/CCR2 expression after graded spinal cord contusion injuries of the rat. J. Neurotrauma 2008 May, 25:427-448.
63. Tysseling V.M., Mithal D., Sahni V., et al. SDF1 in the dorsal corticospinal tract promotes CXCR4+ cell migration after spinal cord injury. J. Neuroinflammation 2011, 8:16.
64. Chalasani S.H., Sabelko K.A., Sunshine M.J., Littman D.R., Raper J.A. A chemokine, SDF-1, reduces the effectiveness of multiple axonal repellents and is required for normal axon pathfinding. J. Neurosci. 2003 Feb 15, 23:1360-1371.
65. Baud V., Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 2001 Sep, 11:372-377.
66. Liefner M., Siebert H., Sachse T., Michel U., Kollias G., Bruck W. The role of TNF-alpha during Wallerian degeneration. J. Neuroimmunol. 2000 Aug 1, 108:147-152.
67. Yang L., Blumbergs P.C., Jones N.R., Manavis J., Sarvestani G.T., Ghabriel M.N. Early expression and cellular localization of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in human traumatic spinal cord injury. Spine 2004 May 1, 29:966-971.
68. Pineau I., Lacroix S. Proinflammatory cytokine synthesis in the injured mouse spinal cord: multiphasic expression pattern and identification of the cell types involved. J. Comp. Neurol. 2007 Jan 10, 500:267-285.
69. Yang L., Jones N.R., Blumbergs P.C., et al. Severity-dependent expression of pro-inflammatory cytokines in traumatic spinal cord injury in the rat. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2005 Apr, 12:276-284.
70. Wang C.X., Olschowka J.A., Wrathall J.R. Increase of interleukin-1beta mRNA and protein in the spinal cord following experimental traumatic injury in the rat. Brain Res. 1997 Jun 13, 759:190-196.
71. Harrington J.F., Messier A.A., Levine A., Szmydynger-Chodobska J., Chodobski A. Shedding of tumor necrosis factor type 1 receptor after experimental spinal cord injury. J. Neurotrauma 2005 Aug, 22:919-928.
72. Lammertse D., Dungan D., Dreisbach J., et al. Neuroimaging in traumatic spinal cord injury: an evidence-based review for clinical practice and research. J. Spinal Cord Med. 2007, 30:205-214.
73. Fehlings M.G., Cadotte D.W., Fehlings L.N. A series of systematic reviews on the treatment of acute spinal cord injury: a foundation for best medical practice. J. Neurotrauma 2011 Aug, 28:1329-1333.
74. Brown P.J., Marino R.J., Herbison G.J., Ditunno J.F. The 72-hour examination as a predictor of recovery in motor complete quadriplegia. Arch. Phys. Med. Rehabil. 1991 Jul, 72:546-548.
75. Harel N.Y., Strittmatter S.M. Functional MRI and other non-invasive imaging technologies: providing visual biomarkers for spinal cord structure and function after injury. Exp. Neurol. 2008 Jun, 211:324-328.
76. DeBoy C.A., Zhang J., Dike S., et al. High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord. Brain J. Neurol. 2007 Aug, 130:2199-2210.
77. Kim J.H., Loy D.N., Wang Q., et al. Diffusion tensor imaging at 3hours after traumatic spinal cord injury predicts long-term locomotor recovery. J. Neurotrauma 2010 Mar, 27:587-598.
78. Cruz C., Cruz F. Spinal cord injury and bladder dysfunction: new ideas about an old problem. TheScientificWorldJOURNAL 2011, 11:214-234.
79. Sahai A., Cortes E., Seth J., et al. Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management. Curr. Neurol. Rep. 2011 Dec, 12:404-412.
80. Panicker J.N., de Seze M., Fowler C.J. Rehabilitation in practice: neurogenic lower urinary tract dysfunction and its management. Clin. Rehabil. 2010 Jul, 24:579-589.
81. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002, 21:167-178.
82. El-Masri W.S., Chong T., Kyriakider A.E., Wang D. Long-term follow-up study of outcomes of bladder management in spinal cord injury patients under the care of the Midlands Centre for Spinal Injuries in Oswestry. Spinal Cord 2012 Jan, 50:14-21.
83. Ku J.H. The management of neurogenic bladder and quality of life in spinal cord injury. BJU Int. 2006 Oct, 98:739-745.
84. Ahmed H.U., Shergill I.S., Arya M., Shah P.J. Management of detrusor-external sphincter dyssynergia. Nat. Clin. Pract. Urol. 2006 Jul, 3:368-380.
85. Madersbacher H., Murtz G., Stohrer M. Neurogenic detrusor overactivity in adults: a review on efficacy, tolerability and safety of oral antimuscarinics. Spinal Cord 2013 Jun, 51:432-441.
86. Santos-Silva A., da Silva C.M., Cruz F. Botulinum toxin treatment for bladder dysfunction. Int. J. Urol. 2013 Oct, 20:956-962.
87. Simpson L.A., Eng J.J., Hsieh J.T., Wolfe D.L. The health and life priorities of individuals with spinal cord injury: a systematic review. J. Neurotrauma 2012 May 20, 29:1548-1555.
88. Mehnert U., Bastien L., Denys P., et al. Treatment of neurogenic stress urinary incontinence using an adjustable continence device: 4-year followup. J. Urol. 2012 Dec, 188:2274-2280.
89. Stöhrer M., Castro-Diaz D., Chartier-Kastler E., Del Popolo G., Kramer G., Pannek J., Radziszewski P., Wyndaele J.-J. Guidelines on neurogenic lower urinary tract dysfunction. EAU Guidelines 2010 2010, European Association of Urology. U. EAo (Ed.).
90. Ochodnicky P., Cruz C.D., Yoshimura N., Michel M.C. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol. Urodyn. 2011 Sep, 30:1227-1241.
91. Ochodnicky P., Cruz C.D., Yoshimura N., Cruz F. Neurotrophins as regulators of urinary bladder function. Nat. Rev. Urol. 2012 Nov, 9:628-637.
92. Cruz C.D. Neurotrophins in bladder function: what do we know and where do we go from here?. Neurourol. Urodyn. 2014 Jan, 33:39-45.
93. Clemow D.B., McCarty R., Steers W.D., Tuttle J.B. Efferent and afferent neuronal hypertrophy associated with micturition pathways in spontaneously hypertensive rats. Neurourol. Urodyn. 1997, 16:293-303.
94. Clemow D.B., Steers W.D., Tuttle J.B. Stretch-activated signaling of nerve growth factor secretion in bladder and vascular smooth muscle cells from hypertensive and hyperactive rats. J. Cell. Physiol. 2000 Jun, 183:289-300.
95. Kuo H.C., Liu H.T., Chancellor M.B. Can urinary nerve growth factor be a biomarker for overactive bladder? Reviews in urology. Spring 2010, 12:e69-e77.
96. Sekerci C.A., Isbilen B., Isman F., Akbal C., Simsek F., Urinary Tarcan T., NGF TGF-beta1, TIMP-2 and bladder wall thickness predict neurourological findings in children with myelodysplasia. J. Urol. 2014 Jan, 191:199-205.
97. Cruz F., Herschorn S., Aliotta P., et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur. Urol. 2011 Oct, 60:742-750.
98. Liu H.T., Chancellor M.B., Kuo H.C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur. Urol. 2009 Oct, 56:700-706.
99. Giannantoni A., Di Stasi S.M., Nardicchi V., et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J. Urol. 2006 Jun, 175:2341-2344.
100. Morichi S., Kashiwagi Y., Takekuma K., Hoshika A., Kawashima H. Expressions of brain-derived neurotrophic factor (BDNF) in cerebrospinal fluid and plasma of children with meningitis and encephalitis/encephalopathy. Int. J. Neurosci. 2013 Jan, 123:17-23.
101. Yang L., Zhang Z., Sun D., et al. Low serum BDNF may indicate the development of PSD in patients with acute ischemic stroke. Int. J. Geriatr. Psychiatry 2011 May, 26:495-502.
102. Krueger F., Pardini M., Huey E.D., et al. The role of the Met66 brain-derived neurotrophic factor allele in the recovery of executive functioning after combat-related traumatic brain injury. J. Neurosci. 2011 Jan 12, 31:598-606.
103. Wang L.W., Han X.M., Chen C.H., Ma Y., Hai B. Urinary brain-derived neurotrophic factor: a potential biomarker for objective diagnosis of overactive bladder. Int. Urol. Nephrol. 2014 Feb, 46:341-347.
104. Antunes-Lopes T., Pinto R., Barros S.C., et al. Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. J. Urol. 2013 Jan, 189:359-365.
105. Sievert K.D., Amend B., Gakis G., et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann. Neurol. 2010 Jan, 67:74-84.